Monument Therapeutics has raised £850k in a funding round led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. Founded by Jenny Barnett, the company applies digital biomarkers to psychiatric drug development.
Its lead programme, MT1988, is a novel fixed-dose combination drug targeting cognitive impairment associated with schizophrenia (CIAS). The treatment has shown strong pre-clinical results by improving cognitive function through nicotinic receptor modulation while mitigating side effects seen in similar drugs. Designed to complement existing antipsychotic medications, MT1988 aims to fill a major treatment gap.
The new capital will support further clinical development, with Phase 1 results expected in Q2 2025, positioning the company to advance its precision psychiatry approach in an area of high unmet need.
